Syntara’s Post

Recent research from MST Access has reaffirmed Syntara's valuation at 𝐀$𝟎.𝟐𝟎/𝐬𝐡𝐚𝐫𝐞, suggesting a 𝟏𝟖𝟔% 𝐮𝐩𝐬𝐢𝐝𝐞 from the current price of A$0.07. Senior Analyst Chris Kallos noted, SNT-5505 demonstrates a unique and promising profile, showing sustained improvements in symptoms and spleen volume with no serious adverse events. Additional interim data expected in 1HCY25 with final results in 2HCY25 #Syntara #SNT #ASX #ASXNews #Biotech #Myelofibrosis #ClinicalTrials